Rheumatoid factors are antibodies directed against the Fc region of immunoglobulin G. First
detected in patients with rheumatoid arthritis 70 years ago, they can also be found in …

Rheumatoid arthritis (RA) is an autoimmune/inflammatory disease affecting 0.5 to 1% of
adults worldwide and frequently leads to joint destruction and disability. Early diagnosis and …

Autoimmune rheumatic diseases are characterised by an abnormal immune system
response, complement activation, cytokines dysregulation and inflammation. In last years …

Background Studies examining the relationship between serological status (rheumatoid
factor and/or anticitrullinated antibody) and rituximab treatment outcome in rheumatoid …

Rheumatoid arthritis is an autoimmune syndrome presenting with chronic inflammation of
the joints. Patients with the same diagnosis can present with different phenotypes. In some …

Objectives To compare the effectiveness of rituximab versus an alternative tumour necrosis
factor (TNF) inhibitor (TNFi) in patients with rheumatoid arthritis (RA) with an inadequate …

There are now five anti-tumour necrosis factor (TNF) drugs licenced for use in rheumatoid
arthritis. This chapter examines the similarities and differences between the drugs and looks …

Objectives. To review studies that address prediction of response to biologic treatment in RA
and to explore the clinical utility of the studied (bio) markers. Methods. A search for relevant …

Objectives This meta-analysis was conducted to investigate whether the status of
rheumatoid factor (RF) and anti-cyclic citrullinated peptide (anti-CCP) antibody are …

Objective To identify if rheumatoid factor (RF) is predictor of response to rituximab (RTX),
abatacept (ABT), and tocilizumab (TCZ) in rheumatoid arthritis (RA). Methods Systematic …